Novo scraps two more heart drug trials, further dimming growth beyond obesity

Novo Nordisk said on Monday it had halted two additional trials of ​its experimental cardiovascular drug ziltivekimab, further denting ‌the Danish drugmaker's efforts to diversify beyond its blockbust...

本文内容来自外部来源，点击「继续访问」将跳转到原始发布站点。